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Abstract
Background: Coronin proteins are known as regulators of actin-based cellular processes, and some of them are
associated with the malignant progression of human cancer. Here, we show that expression of coronin 2A
is up-regulated in human colon carcinoma.
Methods: This study included 26 human colon tumour specimens and 9 normal controls. Expression and localisation of
coronin 2A was studied by immunohistochemistry, immunofluorescence imaging, cell fractionation, and immunoblotting.
Functional roles of coronin 2A were analysed by over-expression and knock-down of the protein. Protein interactions
were studied by co-immunoprecipitation and pull-down experiments, mass spectrometry analyses, and in vitro kinase
and methylation assays.
Results: Histopathological investigation revealed that the expression of coronin 2A in colon tumour cells is up-regulated
during the adenoma-adenocarcinoma progression. At the subcellular level, coronin 2A localised to multiple
compartments, i.e. F-actin stress fibres, the front of lamellipodia, focal adhesions, and the nuclei. Over-expression of
coronin 2A led to a reduction of F-actin stress fibres and elevated cell migration velocity. We identified two novel
direct coronin 2A interaction partners. The interaction of coronin 2A with MAPK14 (mitogen activated protein kinase 14
or MAP kinase p38α) led to phosphorylation of coronin 2A and also to activation of the MAPK14 pathway. Moreover,
coronin 2A interacted with PRMT5 (protein arginine N-methyltransferase 5), which modulates the sensitivity of tumour
cells to TRAIL-induced cell death.
Conclusions: We show that increased expression of coronin 2A is associated with the malignant phenotype of human
colon carcinoma. Moreover, we linked coronin 2A to MAPK14 and PRMT5 signalling pathways involved in tumour
progression.
Background
Colon cancer is one of the most frequent cancers [1]
and its progression is classified into five stages, in which
in stage 0 the cancer involves only the mucosa and in
stage IV the cancer has spread to a distant organ or set
of distant lymph nodes [2]. The majority of colon can-
cers arise from pre-malignant adenomas. Although new
screening methods and early diagnosis have increased
survival rates in the past few years, the mortality rates of
patients diagnosed with one of the later stages are still
very high [3]. Once colon cancer has reached disease
stage IV the five-year survival rate drops to 8.1 % [4]. It
is therefore of major interest to identify cellular path-
ways involved in the migration and invasion of colon
tumour cells.
Coronin proteins belong to the superfamily of eukaryotic-
specific WD40-repeat domain proteins [5]. They play im-
portant roles in the regulation of F-actin dynamics in
numerous cellular processes including the migration and
invasion of tumour cells [6]. Phylogenetic analyses of the
* Correspondence: christoph.clemen@uni-koeln.de
1Center for Biochemistry, Institute of Biochemistry I, Medical Faculty,
University of Cologne, Joseph-Stelzmann-Street 52, 50931 Cologne, Germany
Full list of author information is available at the end of the article
© 2015 Rastetter et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Rastetter et al. BMC Cancer  (2015) 15:638 
DOI 10.1186/s12885-015-1645-7
coronin family of proteins defined seventeen coronin
subfamilies including seven paralogs in mammals [7–9].
Mammalian coronin 2A (synonyms are coronin 4, ClipinB,
IR10, and CRN5; the latter is used in this study) is a
member of the ‘short’ coronin subfamily containing a
single WD40-repeat domain, which adopts the fold of
a seven bladed β-propeller [10]. Compared to other
well-characterized coronins less information is available
about CRN5. In rat mammary adenocarcinoma cells a
knock-down of CRN5 led to reduced cell migration vel-
ocity and increased size, decreased number, and decreased
disassembly of focal-adhesions. Based on the observations
that CRN5 interacts with the cofilin-activating phosphat-
ase Slingshot-1 L and knock-down of CRN5 increases the
amount of phospho-cofilin, CRN5 has been implicated in
the regulation of the focal adhesion turnover rate [11]. In
addition, CRN5 has been identified as a component of the
nuclear receptor co-repressor (NCoR) complex [12] with
a function as an NCoR exchange factor [13]. Here, the
interaction of CRN5 via a SIM-motif (small ubiquitin-like
modifier (SUMO) 2/3 interacting motif) located in its
coiled coil region with SUMOylated liver X receptors
(LXRs) prevents NCoR clearance from target gene pro-
moters. In absence of SUMOylated LXRs CRN5 binds to
oligomeric nuclear actin enabling NCoR clearance and
de-repression of Toll-like receptor-induced inflammatory
response genes in macrophages [13].
The protein kinase MAPK14 is stimulated by pro-
inflammatory signals and environmental stresses such as
heat shock, irradiation, and ultraviolet light leading to its
activation via phosphorylation at Thr180 and Tyr182 by
upstream MAPK kinases 3 and 6 [14]. An involvement
of MAPK14 in colorectal cancer has been shown in
ApcMin colorectal cancer mice, which showed a significant
reduction in tumour size when they were treated with the
MAPK14 inhibitor SB202190 after azoxymethane induc-
tion of colon tumours [15]. However, ablation of MAPK14
in the epithelial cells of the digestive tract of another
mouse strain caused development of significantly more
tumours [16]. In several human colon cancer cell lines the
inhibition of MAPK14 by SB202190 induced growth arrest
and autophagic cell death [17].
Protein arginine methyltransferases are important reg-
ulators of chromatin structure and gene expression, but
are also involved in other cellular processes. PRMT5, a
type II protein arginine methyltransferase enzyme, turned
out to play a role in malignant transformation [18]. More-
over, PRMT5 functions in growth-promoting and pro-
survival signalling pathways. Here, it has been reported that
a knock-down of PRMT5 restored the sensitivity of several
tumour cell lines to TRAIL-induced cell death [19].
In the present study, we demonstrate that the expression
level of CRN5 is associated with the malignant progression
of colon carcinoma, and that CRN5 over-expression led to
elevated tumour cell migration velocity as well as altered
MAPK14 and PRMT5 signalling pathways.
Methods
Immunohistochemistry
Tissue sections of paraffin-embedded human colon spec-
imens comprised six low grade adenoma, five high grade
adenoma, seven adenocarcinoma, five liver metastases,
three lymph node metastases, six normal colon controls,
and three normal (non-affected) lymph nodes. The
normal colon controls were prepared from adjacent
normal tissue of the surgical tissue specimens. After
epitope retrieval using pre-heated sodium citrate buffer,
the sections were immunolabelled with the mouse
monoclonal antibody K77-578-1 directed against human
CRN5. This was followed by blocking of biotin using the
Avidin-Biotin Blocking Kit (Vector Laboratories). The
primary antibody was detected by a biotin-conjugated
rabbit anti-mouse secondary antibody (1:200 for 30 min;
DAKO). Subsequently, avidin-conjugated horseradish
peroxidase (Vector Laboratories) was applied following
the manufacturer’s instructions and visualized by 10 min
3-amino-9-ethylcarbazole (AEC) chromogen (DAKO) in-
cubation. Sections were then counterstained with haema-
toxylin (DAKO), dehydrated, and mounted. The use of
these human tissue specimens for protein expression
studies was approved by the local ethics committee of
the University Hospital of Cologne, informed consent
was obtained from the patients, and the specimens
were procured from the centralized Biobank of the




A7r5 (ATCC CRL-1444) rat smooth muscle cells, CMT93
mouse rectum carcinoma cells (ECACC 89111413), CT26
mouse colon carcinoma cells (ATCC CRL-2638), DLD-1
and WiDr human colon carcinoma cells (ECACC 9010
2540 and 85111501), DHD/K12/TRb rat colonic car-
cinoma cells (ECACC 90062901), HEK293 human em-
bryonic kidney cells (ATCC CRL-1573) and the variant
293TN pseudoviral particle producer cells (BioCat/SBI:
LV900A-1), HeLa human cervix carcinoma cells (ATCC
CCL-2), and U373 human glioblastoma cells (ECACC
89081403) were grown in the recommended nutrition
media at 5 % CO2 and 37 °C. The rationale for using a
particular cell line is given in the Results section.
Antibodies
The following antibodies were used to detect CRN5,
mouse mAb K77-578-1 (newly generated for the pur-
pose of this study; affinity purified from hybridoma
supernatant; dilution 1:500 in 4 % milk powder/PBS for
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western blotting, and 1:100 in 1 % FBS/PBS for immuno-
fluorescence and immunohistochemistry), rabbit pAb
H-110 (SantaCruz sc-66841, 1:500 in 5 % milk powder/
TBS-T), mouse mAb A-3 (SantaCruz sc-271873, 1:250
in TBS-T buffer), and goat pAb L-20 (SantaCruz sc-
32203, 1:250 in 5 % milk powder/TBS-T). Note that
among the purchased CRN5 antibodies pAb H-110
worked best for human cell lysates and recombinant
CRN5, mAb A-3 for mouse cell lines and tissues, and
pAb L-20 for human cell lines and tissues.
β-actin was detected with mouse mAb AC-74 (Sigma
A5316, 1:10,000 in TBS-T), Arp2/3-complex with rabbit
pAb anti-p34 (Upstate 07-227, 1:400 in PBS), GAPDH
by a mouse mAb (Sigma G9295, 1:10,000 in PBS), GFP
with mouse mAb K3-167-2 ([20]; for immunoprecipita-
tion), GST with a rabbit pAb ([21]; 1:50,000 in TBS-T),
lamin B1 with a rabbit pAb (Abcam ab16048, 1:3,000 in
TBS-T), PRMT5 with mouse mAb PRMT5-21 (Sigma
P0493, 1:1,000 in in TBS-T), α-tubulin with rat mAb
YL1/2 ([22], 1:10 in TBS-T), and vinculin with a rabbit
pAb (Sigma V4139, 1:1,000 in 1 % FBS/PBS).
The following antibodies were used to analyse the
MAPK14 pathway (all from Cell Signaling/New England
Biolabs): phospho-MAPK14 (Thr180/Tyr182) rabbit mAb
D3F9 (#4511, 1:1,000 in 5 % BSA/TBS-T), total MAPK14
rabbit pAb (#9212, 1:1,000 in 5 % BSA/TBS-T for western
blotting and 1:100 in in 5 % BSA/PBS for immunofluo-
rescence), phospho-MAPKAPK2 (Thr334) rabbit mAb
(27B7) (#3007, 1:1,000 in 5 % BSA/TBST), total MAP-
KAPK2 rabbit pAb (#3042, 1:1,000 in 5 % BSA/TBS-T),
phospho-Hsp27 (Ser82) rabbit mAb D8A8 (#2401,
1:1,000 in 5 % BSA/TBS-T), total Hsp27 mouse mAb G31
(#2402, 1:1,000 in 5 % milk powder/TBS-T), phospho-
ATF2 (Thr71) rabbit pAb (#9221, 1:1,000 in 5 % BSA/
TBS-T), total ATF2 rabbit mAb 20 F1 (#9226, 1:1,000 in
5 % BSA/TBS-T), phospho-p53 (Ser392) rabbit pAb
(#9281, 1:1,000 in 5 % BSA/TBS-T), and total p53 mouse
mAb 1C12 (#2524, 1:1,000 in 5 % milk powder/TBS-T).
Immunoblotting and immunofluorescence imaging
For immunoblotting, protein samples were separated by
10 %, 12 % or 15 % SDS-PAGE under reducing condi-
tions and proteins were transferred onto PVDF mem-
branes by the wet-blotting method [23].
For immunofluorescence imaging cells were grown on
12 mm coverslips, washed with PBS, fixed in 4 % para-
formaldehyde/PBS for 20 min at room temperature,
permeabilized with 0.5 % Triton X-100 or 0.2 % saponin
in PBS (identical results with both permeabilisation pro-
tocols), incubated in 0.15 % glycine/PBS for 10 min,
washed three times with 0.05 % Triton X-100 or 0.02 %
saponin in PBS, and blocked in 1 % FBS/PBS for 30 min.
Incubation with the primary antibody was done in 1 %
FBS/PBS for two hours, followed by three washes with
PBS for five minutes each, incubation with secondary
antibody AlexaFluor-488 or -568 diluted 1:500 in 1 %
FBS/PBS for one hour, and three more washes with PBS
for five minutes each. Finally, coverslips were rinsed in
water and embedded in Gelvatol [24]. In order to visualise
CRN5 in nuclei, cells were treated with 0.05 % Trypsin for
10 min for epitope retrieval [25] before proceeding to
blocking in 1 % FBS/PBS.
Cell migration assays
Cell migration was measured using μ-slide 8-well cham-
bers with silicone culture-inserts (ibidi #80209, #80826).
40,000 cells were seeded in each chamber and grown for
24 h. After removal of the culture-inserts, which leaves a
500 μm cell-free gap, images were taken every 15 min
for a period of 20 h. Single cell tracking was done using
the “Manual Tracking” (Fabrice Cordelières, Institut
Curie, Orsay, France) plugin and cell path were analysed
using the “Chemotaxis and Migration Tool” (ibidi) plu-
gin for ImageJ (NIH). Directionality is calculated by the
Euclidian divided by the accumulated distance.
Cell fractionation
Purification of nuclei was performed according to [26]. In
brief, washed cell pellets were re-suspended in ice-cold
PBS containing 0.1 % NP-40, and, after lysis, separated by
centrifugation into a cytosolic supernatant and a pellet of
intact nuclei; the latter was washed and centrifuged a
second time before further use.
CRN5-related plasmids
In order to change the cellular expression level of CRN5,
two plasmids for lentiviral transduction were newly
generated. The first, pLKO.1-CRN5-shRNA-puro, was
used for shRNA-mediated knock-down of murine CRN5.
It was generated by annealing oligos CCGGGAGGGA
ACGTCTTGGACATCTCGAGATGTCCAAGACGTTC
CCTCTTTTTT (forward, with adjacent AgeI restric-
tion site overhang) and AATTCAAAAAAGAGGGAA
CGTCTTGGACATCTCGAGATGTCCAAGACGTTCC
CTC (reverse, with adjacent EcoRI restriction site over-
hang), and cloning of the resulting duplex into AgeI/EcoRI
opened pLKO.1-puro. The CRN5 target sequence of
the expressed shRNA is GGAACGTCTTGGACATCAT.
pLKO.1-nontarget-shRNA-puro [27] expressing a non-
target shRNA was used for control experiments. The
second, pLKO.1-CMV-EGFP-CRN5-puro, was used for
over-expression of GFP-CRN5. For its generation, a CRN5




GAGCTGCTCTGAGCCCATCCG) was amplified from
pCMV6-XL4 carrying the human CRN5 cDNA NM_052
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820 (origene SC109892) and inserted into pLKO.1-
CMV-EGFP-MCS-puro [28]. pLKO.1-CMV-EGFP-puro
[28] expressing GFP alone was used as the corresponding
control.
Cell transfection and transduction
Transient transfections of A7r5 and U373 cells were per-
formed by electroporation (Amaxa/Lonza Nucleofector
II, Cell Line Nucleofector Solution V, programs X-001
(A7r5) and T-020 (U373)) and of HEK293 and HeLa
cells by lipid-mediated transfection using Lipofectamine
2000 (Invitrogen). HEK293 cells stably expressing GFP
or GFP-CRN5 were generated by neomycin (G418)
selection.
Lentiviral transduction of CT26 and U373 cells was
performed as described in [27]. In brief, each plasmid of
interest was mixed with three lentiviral packaging plasmids
and co-transfected into 293TN cells. Resulting lentiviruses
were harvested and used to transduce the target CT26 and
U373 cells. After transduction CT26 and U373 cells were
further enriched by addition of 9.00 μg/ml and 0.75 μg/ml
puromycine to the growth medium, respectively.
Microscopy
Immunohistochemistry images were recorded with a
Olympus microscope equipped with the photoP soft-
ware, immunofluorescence images with a Leica TCS
SP5/AOBS/tandem scanning system with emission detec-
tion in sequential mode equipped with the Leica LAS-AF
software (v. 2.6.0.7266), and cell migration images with a
Leica DMI6000B TIRF MC system equipped with software
LAS-AF (v. 2.0.2.2038) and Hamamatsu EM-CCD camera
C9100-02 in bright field (TL-PH) mode.
Affinity purification of tagged proteins from E. coli
GST-CRN5 (above CRN5 cDNA cloned into pGEX-4 T-1),
GST-MAPK14 (MAPK14 cDNA L35264.1 in pReceiver-
B03, GeneCopoeia EX-A1099-B03), and GST (empty
pGEX-4 T-1) were expressed in E. coli strain BL21. Protein
expression was induced at an OD600 of 0.6-0.8 with 0.5-
1 mM IPTG for 2-4 h at room temperature or 37 °C. Cells
were pelleted at 5,000 g for five minutes, re-suspended in
lysis buffer (50 mM Tris/HCl pH 8.0, 150 mM NaCl, 0.5 %
Triton X-100, 2 mM EDTA, 2 mM EGTA, 4 mM DTT,
0.5 mM PMSF, 10 μg/ml aprotinin, 10 μg/ml leupeptin,
2 mM benzamidin, 100 μg/ml lysozyme) for 15 min at
4 °C, snap frozen two times in liquid nitrogen, and
sonicated for two minutes. After centrifugation of the
lysates for 30 min at 13,000 g and 4 °C, the superna-
tants were incubated with glutathione-beads for 2-4 h
at 4 °C, and beads were washed 4-8 times in 20 mM
Tris/HCl pH 8.0, 300 mM NaCl. GST-fusion proteins
were eluted with 20 mM glutathione, 200 mM Tris/HCl
pH 8.0, 2 mM EGTA, 0.1 % Triton X-100. For purification
of untagged MAPK14, beads were incubated with the
TEV protease (enzyme with both GST- and His-tags,
Sigma T4455) in 50 mM Tris/HCl pH 8.0, 150 mM NaCl,
0.5 % Triton X-100.
For purification of His6-PRMT5 (cDNA AF167572.1 in
pReceiver-B01, GeneCopoeia EX-V1247-B01) cells were
lysed in 150 mM Tris/HCl, pH 8.0, 300 mM NaCl,
40 mM imidazole, 0.5 % Triton X-100, 5 % glycerol, 4 mM
DTT, 0.5 mM PMSF, 10 μg/ml aprotinin, 10 μg/ml leu-
peptin, 2 mM benzamidin, 150 μg/ml lysozyme. Ni-beads
were washed with 150 mM Tris/HCl, pH 8.0, 300 mM
NaCl, 40 mM imidazole, 0.5 % Triton X-100, 5 % glycerol,
and eluted in 150 mM Tris/HCl, pH 8.0, 150 mM NaCl,
250 mM imidazole.
Affinity purification of tagged proteins from mammalian
cells
GFP-CRN5 (above CRN5 cDNA cloned into pEGFP-C1)
and GST-MAPK14 (MAPK14 cDNA L35264.1 in
pReceiver-M04, GeneCopoeia EX-A1099-M04) were
over-expressed in HEK293 cells. Cells were scraped off
the culture dishes, washed once with PBS, and lysed in
50 mM Tris/HCl pH 8.0, 150 mM NaCl, 0.5 % Triton
X-100, 2 mM EDTA, 2 mM EGTA, 4 mM DTT, 0.5 mM
PMSF, 10 μg/ml aprotinin, 10 μg/ml leupeptin, 2 mM ben-
zamidin. Supernatants were incubated with GFP-antibody
coated (Miltenyi #130-091-125) or GST-antibody coated
microbeads (Miltenyi #130-091-370) for two hours at 4 °C.
The mixture was passed through μ Columns (Miltenyi),
which had been rinsed with 200 μl of 50 mM Tris HCl
pH 8.0, 150 mM NaCl, 1 % NP-40, 0.5 % sodium deoxycho-
late, 0.1 % SDS, using the Octomacs Separator (Miltenyi).
After four additional washes with 200 μl of this buffer with
addition of 5 mM Mg-ATP and one further wash with
100 μl of 20 mM Tris HCl pH 7.5, the proteins were eluted
by a pH shift; 100 μl 0.1 M triethylamine pH 11 were added
to the columns, and eluates were collected in tubes
containing 13 μl 1 M MES pH 3 for neutralisation.
CRN5 co-immunoprecipitation and pull-down assays
For co-immunoprecipitation lysates of E. coli expressing
GST-CRN5 were incubated with 5-10 μg primary antibody
K77-578-1 (anti-CRN5) and 50 μl Protein G-coated mag-
netic microbeads (Miltenyi #130-071-101) for two hours
at 4 °C. The mixture was passed through μ Columns/
Octomacs Separator and the columns were washed five
times as above. Next, above GST-MAPK14 purified
from HEK293 cells or GST protein from E. coli were
circulated five times through the columns before the
columns were again washed five times (4× 200 μl/1×
100 μl) and eluted with 120 μl of pre-heated SDS-
PAGE sample buffer 50 mM Tris HCl pH 6.8, 50 mM
DTT, 1 % SDS, 1 mM EDTA, 0.005 % bromphenol
blue, 10 % glycerol.
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For pull-down assays glutathione-beads carrying GST-
CRN5 or GST as baits were incubated in 50 mM Tris/
HCl pH 8.0, 150 mM NaCl, 0.5 % NP-40 with either
TEV-protease tag-cleaved MAPK14 or purified His6-
PRMT5 as prey, washed three times with the same
buffer and analysed by SDS-PAGE.
CRN5 immunoprecipitation and co-immunoprecipitation
in conjunction with mass spectrometry
For CRN5 immunoprecipitation and analysis of post-
translational modifications, U373 cells stably over-
expressing GFP-CRN5 were scraped off, washed with
PBS, and re-suspended in 50 mM Tris/HCl pH 8.0,
150 mM NaCl, 1 % NP-40, 2 mM EDTA, 0.5 mM PMSF,
2 mM benzamidin, 10 μg/ml leupeptin, 10 μg/ml aproti-
nin, 5 μM pepstatin A. Cells were homogenised by a tight
douncer (five strokes) and five passages through a 21G
needle. After centrifugation of the cell lysates for 15 min
at 15,000 g and 4 °C, supernatants were incubated with
5-10 μg CRN5 antibody K77-578-1 and 50 μl Protein G
coated sepharose beads for two hours at 4 °C. Beads were
washed five times in PBS/1 % NP-40 and boiled in SDS
sample buffer.
For CRN5 co-immunoprecipitation and detection of
novel binding partners U373 cells stably over-expressing
GFP-CRN5 were used with GFP-antibody coated microbe-
ads as described above. Washing steps were done with
50 mM Tris HCl pH 8.0, 150 mM NaCl, 0.1 % Triton X-
100, and proteins were eluted with pre-heated SDS-PAGE
sample buffer.
Mass spectrometry was performed as described in
[29]. In brief, proteins were separated by SDS-PAGE,
stained with Coomassie brilliant blue, and bands were
excised and proteins were identified after in-gel diges-
tion with V8 or trypsin protease by liquid chromatog-
raphy tandem-mass spectrometry employing a HCT
ETD II iontrap mass spectrometer equipped with a nano
ESI source (Bruker Daltonics, Bremen, Germany). Puta-
tive phosphopeptides (neutral loss of H3PO4) reported
by Mascot searches (“Phosphorylation (ST)” was used as
variable modification) were verified by manual inspec-
tion of the corresponding MS2 spectra.
In vitro kinase assay
Kinase reactions were carried out in 40 μl volume con-
taining 0.2 μg GST-MAPK14, 1 μg GFP-CRN5, 5 μl 8×
kinase buffer (400 mM HEPES pH 8.0, 160 mM MgCl2,
40 mM EGTA, 160 mM β-glycerol phosphate, 8 mM
Na3OV4, 8 mM DTT), and started by addition of 3 μl ATP
mix (0.2 mM ATP, 0.4 μCi/μl γ32P-ATP (GE Healthcare)).
Reaction times vary from 10 to 90 min at 32 °C and were
stopped by adding 8 μl of 5× SDS-PAGE sample buffer.
30 μl of each experiment were resolved by SDS-PAGE, gels
were Coomassie brilliant blue stained, dried and exposed to
Kodak X-Ray films for 72 h. Controls were without GFP-
CRN5 or GST-MAPK14, or in the presence of 92.5 μM
MAPK14 inhibitor SB202190.
Analysis of the MAPK14 signalling pathway
200,000 HEK293 cells over-expressing GFP-CRN5 or
GFP were seeded in 6-well plates, grown overnight,
exposed to heat shock at 42 °C for 0, 15, and 30 min
according to [30], washed with PBS, and finally lysed in
SDS-PAGE sample buffer for immunoblotting analyses.
Cells were counted using a TC10TM automated cell
counter (Bio-Rad Laboratories GmbH); GAPDH was
used as a loading control.
In vitro methylation assay
10 μl (350 ng) recombinant FLAG-PRMT5 in a complex
with its activator His6-MEP50 purified from insect cells
(BPS Bioscience # 51048; buffer was exchanged to 0.1 M
Tris pH 8.0 using illustra NAP-5 gel filtration columns
(GE Healthcare)), 20 μl (1.5 μg) full-length GFP-CRN5
purified from mammalian HEK293 cells (see above),
which were treated with 20 mM adenosine dialdehyde
(AdOx, inhibitor of S-adenosylhomocysteine nucleosi-
dase) for 24 h before purification, or control substrates
or elution buffer (no substrate), 5 μl 3H-labelled S-
adenosylmethionine (PerkinElmer NET155, 0.55 mCi/ml,
15 Ci/mmol), and 0.1 M Tris pH 8.0 up to a final reaction
volume of 57 μl were incubated for 4 h at 37 °C. Subse-
quently, proteins were methanol/chloroform precipitated
and washed, solubilised in 100 μl 0.1 M HCl, 2 % SDS,
and mixed with 4 ml Quicksafe A (Zinsser Analytic) to
measure the 3H disintegrations per minute (dpm) in a
scintillation counter (Wallac 1400 DSA version 2.4; proto-
col “easy count”, counting time 60 s).
TRAIL resistance assay
HeLa cells were seeded in 6-well plates, transiently
double-transfected on the next day at 30 % confluence
with the following combinations of expression plasmids:
empty pLKO.1-puro/empty pCMV-3xFLAG-6, PRMT5-
shRNA oligo gatggacaatctggaatct (targets mouse and
human PRMT5; GeneCopoeia MSH031088-HIVmU6-
3-OS304859)/empty pCMV-3xFLAG-6, empty pLKO.1-
puro/FLAG-CRN5 (above CRN5 cDNA cloned into
pCMV-3xFLAG-6), and PRMT5-shRNA/FLAG-CRN5.
24 h after transfection growth medium was exchanged
and one set of transfected cells received 50 ng/ml human
TRAIL ligand (Enzo Life Sciences, SuperKillerTRAIL,
ALX-201-115). After incubation for further 24 h cell
proliferation rates were determined with the Quick cell
proliferation assay Kit II (BioVision) employing the Tecan
Infinite M1000 plate reader (absorbance values at 440 nm
(dye) and at 650 nm (control/reference), multiple posi-
tions per well, measurements 0, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0 h
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Fig. 1 (See legend on next page.)
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after addition of the dye reagent) before the cells finally
were harvested for SDS-PAGE and immunoblotting.
Data analysis and figure preparation
Data analyses and statistical evaluations were performed
using Excel 2010 (Microsoft); column charts indicate
mean values and standard deviations; statistical signifi-
cance levels were calculated by Student’s t-test; the num-
bers of independent experiments are given in the Results
section or Figure Legends. Final assembly and prepar-
ation of all figures for publication was done using Corel
Draw Graphics Suite X4.
Results
CRN5 expression is up-regulated in colon carcinoma
Expression of CRN5 in human colon tumours was inves-
tigated by histopathological analyses using our mouse
monoclonal antibody K77-578-1. In normal colon tissue
neither epithelial nor stroma cells did express CRN5,
while tissue-residing lymphocytes showed a strong cyto-
solic localisation of CRN5 (Fig. 1a; intense reddish stain
marked by double-arrows). In low grade adenoma few
epithelial cells were detected, which expressed CRN5 in
the cytosol. Upon further de-differentiation into high
grade adenoma virtually all tumour epithelial cells were
positive for CRN5 (Fig. 1b). In adenocarcinoma, CRN5
was additionally present in the nuclei of a subset of the
tumour epithelial cells. Moreover, fibroblasts of the
tumour stroma were also positive for CRN5 (Fig. 1c).
This pattern of CRN5 expression in both tumour epithe-
lial and stroma cells was also visible in liver and lymph
node metastases (Fig. 1d, e). Semi-quantitative analysis
showed that the tumour epithelial cells in all tissue spec-
imens of high grade adenoma, carcinoma and metastases
were CRN5 positive. In contrast, only in one third of the
low grade adenomas CRN5 expression was found, while
normal colon epithelial cells were negative for CRN5
(Additional file 1: Figure S1A). CRN5-positive stroma
cells were restricted to colon carcinoma and metastases.
Presence of CRN5 in nuclei of tumour epithelial cells
was only evident in carcinoma and metastases (Additional
file 1: Figure S1B).
Two antibodies, our mouse mAb K77-578-1 and the
commercially available rabbit pAb L-20, were used for
immunoblotting in order to compare the expression
levels of CRN5 in colon tissue specimens. Both antibodies
showed that the CRN5 signal intensity did not increase in
colon carcinoma as compared to normal human colon
tissue (Additional file 2: Figure S2A, B, left parts). This
finding did, however, not contradict the CRN5 expression
pattern seen by immunohistochemistry, as in the presence
of an already strong expression of CRN5 in tissue-residing
lymphocytes in the normal colon tissue (Fig. 1a, left image,
double-arrow), the additional expression of CRN5 in colon
epithelial tumour cells did not lead to an obvious increase
of the overall CRN5 signal intensity in immunoblotting.
Both antibodies detected CRN5 predominantly as a band
of 48 kDa in normal colon and colon carcinoma tissues
(Additional file 2: Figure S2A, B, left parts). This band was
the exclusive signal of CRN5 in the WiDr and DLD-1
human colon carcinoma cell lines (Additional file 2:
Figure S2A, B, right parts); and also murine CT26 and
CMT93 and rat DHD/K12/TRb colon carcinoma cell lines
solely showed this 48 kDa band (data not shown). In
murine colon and non-colon cell lines (Additional file 2:
Figure S2C, D), however, our own mouse mAb K77-578-1
and the three commercially available antibodies, i.e. goat
pAb L-20, rabbit pAb H-110 (not shown), and mouse
mAb A-3, detected CRN5 at the expected position of
56 kDa (calculated molecular mass 59.8 kDa). Specificity
of our mAb K77-578-1 was further verified by detection of
a GFP-CRN5 fusion protein (Additional file 2: Figure S2D).
CRN5 is present in nuclei, at F-actin stress fibres, and the
front of lamellipodia
To address the re-localisation of CRN5 into the nucleus,
which we had seen in the colonic tissue specimens, we
used CT26 mouse colon carcinoma cells. A nuclear local-
isation of endogenous CRN5 was also detected in these
cells after epitope retrieval (Fig. 2a). Nuclear CRN5 was
further verified by fractionation experiments using HeLa
cells, which could easily be transfected to over-express
FLAG-CRN5 (Fig. 2b). We also studied the cytosolic lo-
calisation of CRN5 in more detail, as a previous study
(See figure on previous page.)
Fig. 1 CRN5 is over-expressed in human colon cancer and is present in the nucleus of a subset of tumour cells. a Transverse section of normal human
colon tissue. Colon epithelium cells (arrowheads) and fibroblasts of the stroma (arrow) did not express CRN5, while tissue-resident lymphocytes exhibited a
marked expression of CRN5 (double-arrows). b Section of an adenoma with a low grade (lower right region) and a high grade part (upper left region). In the
more benign part only single epithelial cells were faintly positive for CRN5 (white arrowhead). In contrast, all epithelial cells of the high grade part showed a
strong cytosolic stain of CRN5 (arrowheads). In both parts stroma fibroblasts were CRN5-negative (arrow), and lymphocytes displayed the marked CRN5
signal (double-arrows). c Section of an adenocarcinoma with virtually all tumour epithelial cells showing a strong cytosolic CRN5 expression (arrowhead).
Furthermore, a signal for CRN5 was present in the nuclei of tumour epithelial cells (double-arrowheads). In addition to the lymphocytes (double-arrow),
stroma fibroblasts (arrow) were CRN5-positive in the adenocarcinoma. d, e Sections of liver and lymph node metastases, where a strong
CRN5 signal intensity was visible in the cytoplasm (arrowheads) and nuclei (double-arrowheads) of the tumour epithelial cells. Tumour stroma cells
(arrows) and lymphocytes (double-arrows) also showed CRN5 expression. The images at higher magnification (right column) were taken from the same
section except for the high grade adenoma, which was from another tissue specimen
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suggested the exclusive presence of CRN5-GFP at focal
adhesions [11]. We found that the localisation of CRN5
was strongly dependent on the cell type. While GFP-
CRN5 indeed co-localised with vinculin at focal adhesions
in HeLa human cervical cancer cells (data not shown), it
was also present at other actin structures, for example at
F-actin stress fibres in A7r5 rat smooth muscle cells and
the front of lamellipodia in U373 human glioblastoma
cells (Fig. 2c, d). Moreover, we noted that stable over-
expression of GFP-CRN5 in U373 cells almost com-
pletely suppressed F-actin stress fibres and caused the
formation of multiple long extensions enriched in
GFP-CRN5 at the rear of the cells (Fig. 2e). These effects
were specific for CRN5, as they could not be observed in
U373 cells over-expressing the coronin paralog CRN2
(Fig. 2f).
CRN5 expression level correlates with cell migration
velocity
To further analyse the role of CRN5 in tumour cell
migration, we aimed at knocking down CRN5 in cell
lines derived from human colon carcinoma. We used a
lentiviral transduction protocol to express shRNA oligos
directed against CRN5 in human WiDr and DLD-1 cells.
We tested 12 different shRNA oligos, but none of them
had a significant effect on the CRN5 expression level,
although transduction and expression of a non-target
shRNA worked. Two of the shRNAs we used targeted
sequence stretches of CRN5 paralogous to sequences
successfully used for knock-down of CRN2 [27]. Using a
commercially available siRNA pool (Thermo Scientific
Dharmacon, containing siRNAs J-011420-05, J-011420-
06, J-011420-07, J-011420-08) also did not lead to a
CRN5 knock-down. We therefore changed to murine
and rat cell lines and employed murine CT26 and
CMT93 and rat DHD/K12KTRb colon carcinoma cells
for further tests of CRN5-specific shRNAs. Using a
shRNA that targets the sequence GGAACGTCTTGGA
CATCAT, which is comparable to the one used for
RAW264.7 murine macrophages [13] and identical, but
independently designed, to the one used for MTLn3 rat
mammary adenocarcinoma cells [11], we finally could
generate a knock-down of CRN5, however, only in CT26
cells. This CRN5-specific shRNA led to a moderate
reduction of CRN5 expression of approximately 40 %
both at the mRNA and protein level (Fig. 3a). These cells
were subjected to cell migration and in vitro wound heal-
ing assays. Analysis of the CT26 non-target shRNA con-
trol cells showed a mean migration velocity of 32.1 μm/h
and a directionality of 0.66. Knock-down of CRN5 re-
sulted in a significantly reduced migration velocity of
24.1 μm/h and an increased directionality of 0.74. In
addition, the overall gap closure was decreased in the
knock-down cells, but did not reach statistical significance
(Fig. 3c).
When we next tried to over-express CRN5 in the
above cell lines, we encountered similar difficulties. Nei-
ther by means of transfection nor lentiviral transduction
we were able to generate any colon carcinoma cell line
with stable over-expression of GFP-CRN5. However,
U373 human glioblastoma cells, which we used as a
control for the lentiviral transduction procedure, eventu-
ally showed a stable GFP-CRN5 over-expression (Fig. 3b).
Analysis of these cells showed that U373 cells expressing
GFP for control migrated with a mean velocity of
11.9 μm/h and a directionality of 0.8. In contrast, GFP-
CRN5 over-expressing U373 cells migrated with an in-
creased velocity of 17.3 μm/h and a decreased directionality
of 0.5; the overall gap closure was not significantly changed
(Fig. 3d). Although CT26 and U373 cells displayed different
basal values for migration, the overall effect of a higher
CRN5 expression level was a faster cell migration in
conjunction with reduced directionality, while a decrease in
CRN5 expression had the opposite effect.
MAPK14 phosphorylates CRN5 at S423
We performed co-immunoprecipitation and pull-down
experiments in order to identify novel, tumour-related
post-translational modifications and binding partners of
CRN5. Mass spectrometry analyses of GFP-CRN5 immu-
noprecipitated from U373 cell lysates revealed phosphor-
ylation of serine 423 (Fig. 4a). This residue is located
within the C-terminal extension of CRN5 and is part of a
MAPK14 target consensus motif [31]. To investigate a
possible direct interaction between both proteins, pull-
down assays were carried out with recombinant purified
(See figure on previous page.)
Fig. 2 CRN5 localises to the nucleus, F-actin stress fibres, and lamellipodia. a Cytosolic and nuclear (arrows) localisation of CRN5 in CT26 mouse colon
carcinoma cells. Detection was done with pAb H-110. Cells were fixed with 4 % paraformaldehyde, permeabilised with Triton X-100, and treated with
0.05 % Trypsin for 10 min for epitope retrieval according to [25]. Secondary antibody, goat anti-mouse AlexaFluor 488; nuclei were visualized with DAPI.
b Nuclei of HeLa cells over-expressing FLAG-tagged CRN5 were isolated, and presence of CRN5 was determined by pAb H-110 immunoblotting. For
control, the same membrane was labelled with lamin B1 (nuclear envelope) and α-tubulin (cytoplasm) antibodies. c In A7r5 aortic smooth
muscle cells GFP-CRN5 localised to F-actin stress fibres; arrows label a cell-cell contact. F-actin was visualised using TRITC-phalloidin. d In
U373 human glioblastoma cells GFP-CRN5 co-localised with the Arp2/3 complex (anti-p34 antibody) at the front of lamellipodia (arrows).
e, f U373 human glioblastoma cells over-expressing GFP-CRN5 or GFP-CRN2. While GFP-CRN2 was strongly enriched at all F-actin structures including
stress fibres, the presence of GFP-CRN5 led to depletion of F-actin stress fibres (asterisk) and induced extensions at the rear of the cells (arrowheads)
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MAPK14 isolated either from E. coli BL21 or HEK293
cells in conjunction with bacterially expressed GST-
CRN5. Note that MAPK14 derived from mammalian cells
is phosphorylated and active, whereas the bacterially
expressed protein is non-phosphorylated and enzymati-
cally inactive (Fig. 4b). GST-CRN5 was pre-incubated with
CRN5 mAb K77-578-1 coupled to Protein G-coated mag-
netic microbeads and then incubated with GST-MAPK14
or GST for control, both purified from HEK293 cells
(Fig. 4c). Similarly, MAPK14 purified from E. coli was in-
cubated with GST-CRN5 or GST coupled to glutathione-
sepharose beads (Fig. 4d). These experiments showed that
CRN5 directly binds to both non-phosphorylated and
phosphorylated MAPK14. At the cellular level, we ob-
served a co-localisation of both proteins at the front of
lamellipodia (Fig. 4e). Finally, we performed in vitro kinase
assays to verify that CRN5 is a substrate of MAPK14.
Incubation of both proteins led to a time-dependent
increase of the CRN5 phosphorylation signal. Specificity
of the reaction was confirmed using the ATP-competitive
MAPK14 kinase inhibitor SB202190, which markedly
suppressed CRN5 phosphorylation (Fig. 4f).
Over-expression of CRN5 activates the MAPK14 signalling
pathway
We next investigated whether CRN5 plays a role in
MAPK14 activation. For this purpose we used a set of
antibodies to determine the amounts of total and phos-
phorylated MAPK14, downstream kinases, and sub-
strates. We used HEK293 cells for these experiments,
because heat shock treatment of the control cells express-
ing GFP resulted in a clear, time-dependent increase of
MAPK14 phosphorylation. In contrast, HEK293 cells that
over-expressed GFP-CRN5 already showed a two-fold
increased MAPK14 phosphorylation at basal conditions
with no further increase upon heat shock stimulation, and
the total MAPK14 content did not change (Fig. 5a).
Furthermore, the downstream kinase MAPKAPK2 as well
as the cytosolic (Hsp27) and nuclear (activating transcrip-
tion factor (ATF2) p53) substrates of MAPK14 showed
increased phosphorylation levels in the GFP-CRN5 over-
expressing cells (Fig. 5b).
CRN5 is a substrate of PRMT5 and increases TRAIL
receptor sensitivity
Our co-immunoprecipitation and pull-down experiments
also led to the identification of the 72 kDa protein PRMT5
(protein arginine N-methyltransferase 5) as a novel, direct
CRN5 binding partner (Additional file 3: Figure S3A, B).
We performed 3H-labelled S-adenosylmethionine in vitro
methylation assays and found that CRN5 is a substrate of
PRMT5 (Additional file 3: Figure S3C). In a next step, we
investigated the effect of CRN5 on TRAIL (TNF-Related
Apoptosis-Inducing Ligand)-induced cell death, as a previ-
ous study had identified PRMT5 as a novel TRAIL
receptor-binding protein, whose knock-down restored the
sensitivity of several tumour cell lines to TRAIL-induced
cell death [19]. We used HeLa cells, a well-established
TRAIL-resistant cell line [32], to investigate the effect of
CRN5 over-expression with and without additional PRMT5
knock-down on the TRAIL receptor pathway (Additional
file 3: Figure S3D; note, that HeLa cells virtually lack
endogenous CRN5). Knock-down of PRMT5 had no effect
on cell proliferation in absence of TRAIL, while expression
of FLAG-CRN5 increased cell proliferation by approxi-
mately 20 % (Additional file 3: Figure S3E, dark columns).
Although in our experiments the addition of TRAIL ligand
to HeLa cells control-transfected with empty vectors
already caused a 40 % reduction of the cell number,
knock-down of PRMT5 resulted in a further 10 %
decrease (Additional file 3: Figure S3E, light columns
left and right panels). Both, over-expression of FLAG-
CRN5 alone and in combination with PRMT5 knock-
down reduced the cell number by approximately 20 %
(Additional file 3: Figure S3E, light columns right panel).
Discussion
Our CRN5 immunohistochemistry analysis revealed an
increase of the CRN5 expression level in colon tumour
cells during adenoma-adenocarcinoma progression. In
addition, our cell migration experiments showed that a
higher CRN5 expression level causes an increased
tumour cell migration velocity. Although this is the first
report on a putative function of CRN5 in the malignant
progression of cancer, it seems to be a general patho-
physiological feature of coronin proteins. Previous studies
(See figure on previous page.)
Fig. 3 Expression of CRN5 increases cell migration velocity. a Lentivirus-mediated expression of a CRN5-specific shRNA caused an approximately
40 % reduction of both the CRN5 mRNA and protein levels in CT26 mouse colon carcinoma cells. A representative immunoblot and agarose gel
as well as corresponding densitometry values are shown. CT26 control cells expressed a non-target (nt) shRNA. b Lentivirus-mediated GFP-CRN5
over-expression in U373 human glioblastoma cells led to a 3.8-fold increase of the total CRN5 protein level as compared to control cells expressing
only GFP. A representative immunoblot as well as densitometry values are shown. c CT26 cells expressing the non-target or CRN5-specific shRNA
(knock-down, kd) and (d) U373 cells over-expressing GFP or GFP-CRN5 were used for analysis of cell migration employing in vitro wound healing assays.
Plot graphs show two-dimensional migration patterns of individual cells. Column charts indicate mean values and standard deviations of migration
velocity and directionality (CT26 cell lines, n = 96 cells each; U373 cell lines, n = 150 cells each) as well as wound closure (CT26 cell lines, n = 6 gaps
each; U373 cell lines, n = 10 gaps each)
Rastetter et al. BMC Cancer  (2015) 15:638 Page 11 of 16
Fig. 4 (See legend on next page.)
Rastetter et al. BMC Cancer  (2015) 15:638 Page 12 of 16
reported an involvement of the paralog CRN2 (synonyms
are: Coro1C, coronin 3, hCRNN4) in multiple types of
cancer. In human diffuse gliomas the number of CRN2
positive tumour cells was correlated with the malignant
phenotype of diffuse gliomas [27], and an increased CRN2
expression level promoted glioblastoma cell invasion [28].
Over-expression of CRN2 also enhanced cell migration
in BEL-7402 human hepatocellular carcinoma [33] and
in MKN28-NM gastric cancer cells [34]. Other studies
showed increased CRN2 protein expression related to
progression of dysplastic naevi [35], the clinical pro-
gression and pulmonary metastasis of hepatocellular
carcinoma [36], the pathogenesis of primary effusion
lymphoma [37], and the presence of lymph node me-
tastases in gastric cancer [34]. Increased CRN2 mRNA
levels were correlated to further tumour types with
poor clinical prognosis [38–41]. For another coronin
paralog, CRN4 (synonyms are: coronin 1A, coronin 1,
ClipinA, Taco, p57), published data indicated increased
expression levels in breast cancer [42–44].
A role of coronin proteins in tumour progression is not
surprising, as basic characteristics of various coronin pro-
teins are their interaction with actin polymers as well as
the regulation of actin cytoskeleton dynamics [6]. Gener-
ally, the actin cytoskeleton is highly important for the
processes of tumour cell migration and invasion [45]. In
this respect, we found that CRN5 not only localises
to F-actin enriched cell compartments including F-
actin stress fibres, the front of lamellipodia and focal
adhesions, but also modulates the actin cytoskeleton
by reducing the number of F-actin stress fibres lead-
ing to an elevated cell migration velocity. However,
coronin proteins do not only regulate actin dynamics
via direct interaction with F-actin, but also by modulation
of related signalling pathways [46–50]. The finding
that CRN4 is involved in calcium homeostasis [51, 52]
and CRN5 in the expression of inflammatory response
genes via NCoR complex clearance in immune cells
[13] fulfils the expectation that the β-propeller fold of
coronin proteins serves as platform for multiple protein-
protein interactions. We therefore have searched for
novel and tumour related CRN5 binding partners by co-
immunoprecipitation experiments, mass spectrometry
analyses, and pull-down assays. Amongst several newly
identified proteins MAPK14 and PRMT5 were related to
tumourigenesis. Pharmacological inhibition of MAPK14
inhibited growth of colon cancer cell lines [17] and colon
tumour growth in mice [15]. In our experiments the
interaction of CRN5 with MAPK14 led to phosphorylation
of CRN5. In addition, cells that over-expressed CRN5
showed an activation of the MAPK14 pathway suggesting
an involvement of CRN5 in tumour progression via the
MAPK14 signalling pathway. With regard to PRMT5 it
has been reported that a knock-down of this methyl
transferase restored the sensitivity of several tumour cell
lines to TRAIL-induced cell death [19]. We found that
CRN5 is methylated by PRMT5 and that over-
expression of CRN5 also increased the sensitivity to
TRAIL-induced cell death. This latter, rather anti-
oncogenic effect might become relevant in conjunction
with cancer treatment.
Taken together, our present work links the expres-
sion level of CRN5 with the malignant progression of
colon cancer. Further, our results suggest that CRN5
affects tumour-related cell functions on several levels,
directly on the actin cytoskeleton and more indirectly
via modulation of the MAPK14 and PRMT5 signal-
ling pathways.
(See figure on previous page.)
Fig. 4 MAPK14 phosphorylates CRN5 at serine 423. a GFP-CRN5 was immunoprecipitated from lysates of U373 cells using mAb K77-578-1. The GFP-CRN5
band at 83 kDa was cut from the Coomassie stained gel, subjected to mass spectrometry, and a phosphorylation was identified at serine 423 (highlighted
in black). Underlined, MAPK14 phosphorylation consensus target motif. Amino acid sequences highlighted in grey indicate the sequence coverage by mass
spectrometry. b GST-MAPK14 expressed in E. coli BL21 and HEK293 cells. MAPK14 derived from the latter is phosphorylated at Thr180 and
Tyr182 as determined by phospho-MAPK14 pAb D3F9, and is visible at a slightly higher molecular weight than the non-phosphorylated
protein derived from the bacteria. c Co-immunoprecipitation studies were carried out using the CRN5 mAb K77-578-1 coupled to Protein
G-coated magnetic microbeads (Miltenyi), which were first incubated with GST-CRN5 purified from E. coli BL21 and afterwards incubated
with either GST-MAPK14 purified from HEK293 cells or GST purified from E. coli BL21 for control. Analysis was done by GST rabbit pAb
[21] immunoblotting. d A pull-down assay was performed using GST-CRN5 or GST coated glutathione-sepharose beads together with
non-tagged MAPK14. All three recombinant proteins were purified from E. coli BL21 as GST-fusion proteins; from MAPK14 the tag was
cleaved by TEV-protease. Analysis was performed using CRN5 mAb K77-578-1, MAPK14 rabbit pAb, and the GST pAb. c, d For illustration
purposes the order of lanes from the original immunoblots were digitally re-arranged to omit dispensable lanes. e Immunofluorescence
images show an enrichment and co-localization of CRN5 and MAPK14 at the front of lamellipodia (arrows). U373 cells stably over-expressing GFP-CRN5
were methanol fixed; detection of MAPK14 was done with pAb #9212 and secondary antibody goat anti-mouse AlexaFluor 568. f In vitro kinase assay
employing full-length GFP-CRN5 and GST-tagged MAPK14 purified from HEK293 cells. Time course (10, 20, 60, 90 min) of phosphate incorporation from
[γ-32P]ATP into GFP-CRN5. As controls the selective, ATP-competitive MAPK14 kinase inhibitor SB202190 was used, and samples lacking GST-MAPK14 or
GFP-CRN5. Left panel, autoradiograph (32P); right panel, corresponding Coomassie brilliant blue stained gel. Note, that the part of the autoradiograph
showing the time-dependent phosphorylation of GFP-CRN5 is presented with increased contrast settings (dotted rectangle), because of the
high background signals from MAPK14 autophosphorylation
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Conclusions
This is the first time it has been reported that in-
creased expression of coronin 2A/CRN5 is associated
with the colorectal adenoma-adenocarcinoma pro-
gression. Over-expression of CRN5 does not only
induce cytoskeletal alterations, but also changes of
the MAPK14 and PRMT5 signalling pathways. The
present study adds further evidence that members of
the coronin family of actin regulatory proteins play
important roles in cancer progression.
Fig. 5 Over-expression of CRN5 activates the MAPK14 signalling pathway. a HEK293 cells stably over-expressing GFP for control (left upper
panel) or GFP-CRN5 (right upper panel) were exposed to heat shock (0, 15, 30 min at 42 °C). Levels of Thr180/Tyr182-phosphorylated
MAPK14 (pp38α) were determined by immunoblotting. Total MAPK14 (p38α, time point 0 min/without heat shock) and GAPDH of the
heat shock experiment are shown for control (right lower panel). Densitometric analysis from five independent assays at time point 0
without heat shock (column chart with mean values and standard deviations; values were normalised to the GAPDH signals and indexed
to GFP cells) revealed a two-fold increase of MAPK14 phosphorylation in cells expressing GFP-CRN5. b Analysis of the phosphorylation
level of selected substrates downstream of MAPK14 revealed an activation of the MAPK14 pathway in GFP-CRN5 expressing HEK293 cells
(Thr334-phosphorylated MAPKAPK2, Ser82-phosphorylated Hsp27, Thr71-phosphorylated ATF2, Ser392-phosphorylated p53). Loading control,
see GAPDH in (a, right lower panel)
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Additional files
Additional file 1: Figure S1. Expression level and nuclear localisation
of CRN5 are associated with the malignancy of colon tumours.
(A) Semi-quantitative analysis (per cent values) of the expression of
CRN5 in normal and tumour epithelial cells, stroma cells, and lymphocytes
as seen in Fig. 1. (B) Semi-quantitative analysis (per cent values) of the
presence of CRN5 in the cytoplasm or nuclei of tumour epithelial cells as
seen in Fig. 1. N, number of diagnostic tissue specimens. Asterisk, only two of
the six specimens from low grade adenoma showed CRN5 expression in
tumour epithelial cells. (TIFF 225 kb)
Additional file 2: Figure S2. CRN5 immunoblotting indicates two
bands with molecular weights of 56 and 48 kDa. The immunoblotting
pattern of mouse mAb K77-578-1 was compared with the commercially
available CRN5 antibodies L-20 and A-3. The antibodies detected endogenous
CRN5 at 56 and 48 kDa in human colon tissues; total protein amounts of the
tissue lysates were determined and identical amounts loaded onto the gel.
Specificity of mAb K77-578-1 was further verified by detection of a GFP-CRN5
fusion protein. For illustration purposes lanes from different original
immunoblots were digitally combined. Hs, homo sapiens; Mm, mus
musculus. (TIFF 277 kb)
Additional file 3: Figure S3. CRN5 is methylated by PRMT5, increases
cell proliferation, and sensitises cells to TRAIL-induced cell death.
(A) Co-immunoprecipitation experiment using lysates from U373 cells
with stable over-expression of GFP-CRN5 and anti-GFP magnetic
microbeads. Precipitates were subjected to SDS-PAGE, stained with
Coomassie brilliant blue, and proteins were identified by mass spectrometry
analysis. Arrows indicate the positions of GFP-CRN5 and PRMT5.
(B) Pull-down assay using GST-CRN5 or GST for control coupled to
glutathione-coated sepharose beads and soluble His6-PRMT5 confirm
a direct interaction of CRN5 and PRMT5. Proteins were expressed and
purified from E. coli strain BL21. Asterisk, GST signal from partial degradation
of GST-CRN5. For illustration purposes the order of lanes from the original
immunoblots were digitally re-arranged to omit dispensable lanes.
(C) In vitro methylation experiments based on the incubation of recombinant
PRMT5/MEP50 complex, GFP-CRN5, and 3H-labelled S-adenosylmethionine
showed methylation of CRN5. Controls lacked the substrate GFP-CRN5.
Columns indicate mean values and standard deviations derived from three
independent experiments. (D) Immunoblot verifications of PRMT5 knock-
down and FLAG-CRN5 over-expression in HeLa cells. (E) Left panel: HeLa
cell viability after double-transfections as indicated in absence (dark
columns) and presence (light columns) of TRAIL ligand. Viability of control
cells transfected with both empty vectors is set to 100 %. One representative
out of ten independent experiments with similar patterns of cell viability is
shown; note, that the level of absolute absorbance values varied from
experiment to experiment and did not allow calculation of a mean value.
Right panel: For better illustration of the results the three light columns
indicate the decrease of cell viability, i.e. the rate of TRAIL-induced
cell death. This was calculated by the differences of the values from the three
right pairs of dark and light bars from the left panel minus the TRAIL-induced
decrease of cell viability of the control cells (first left pair of bars). (TIFF 521 kb)
Abbreviations
AdOx: Adenosine dialdehyde; AEC: 3-amino-9-ethylcarbazole;
ATCC: American type culture collection; BSA: Bovine serum albumin;
CRN: Coronin; DTT: Dithiothreitol; ECACC: European collection of cell cultures;
EDTA: Ethylenediaminetetraacetic acid; EGFP: Enhanced green fluorescent
protein; EGTA: Ethylene glycol tetraacetic acid; ESI: Electrospray ionization;
FBS: Foetal bovine serum; GAPDH: Glyceraldehyde 3-phosphate
dehydrogenase; GST: Glutathione S-transferase; LXR: Liver X receptor;
MAPK14: Mitogen activated protein kinase 14 MAP kinase p38α; NCoR: Nuclear
receptor co-repressor; NP-40: Octylphenoxypolyethoxylethanol Nonidet P-40,
IGEPAL CA-630; PBS: Phosphate buffered saline; PMSF: Phenylmethylsulfonyl
fluoride; PRMT5: Protein arginine N-methyltransferase 5; PVDF: Polyvinylidene
difluoride; SDS-PAGE: Sodium dodecyl sulfate polyacrylamide gel
electrophoresis; shRNA: Small hairpin ribonucleic acid; siRNA: Small interfering
ribonucleic acid; SUMO: Small ubiquitin-like modifier; TBS-T: Tris-buffered
saline with Tween 20 detergent; TEV: Tobacco etch virus; TRAIL: Tumour
necrosis factor related apoptosis inducing ligand.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
RHR, MB, UD, MM, JB, and CSC designed and performed experiments and
analysed data. RS, SH, KB, CMW and FTW performed experiments and
analysed data. MO, AZ and LE designed experiments and analysed data. RHR
and CSC reviewed all data, prepared the figures, and wrote the manuscript.
All authors approved the final version of the manuscript.
Acknowledgements
This work was supported by grant CL 381/2-1 of the German Research
Foundation (DFG) awarded to CSC, and Köln Fortune grant 141/2011 awarded
to RHR and CSC. We thank Maria Stumpf for excellent technical support. We are
grateful to Reginald O. Morgan and Stefan Müller for helpful discussions.
Author details
1Center for Biochemistry, Institute of Biochemistry I, Medical Faculty,
University of Cologne, Joseph-Stelzmann-Street 52, 50931 Cologne, Germany.
2Institute of Pathology, University Hospital of Cologne, 50931 Cologne,
Germany. 3Institute for Genetics, University of Cologne, 50674 Cologne,
Germany. 4Max Planck Institute for Neurological Research, 50931 Cologne,
Germany. 5Present address: Department of Anatomy and Developmental
Biology, Monash University, Clayton, VIC 3800, Australia.
Received: 7 April 2015 Accepted: 4 September 2015
References
1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer
J Clin. 2005;55:74–108.
2. Centelles JJ. General aspects of colorectal cancer. ISRN oncology.
2012;2012:139268.
3. Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B, et al.
Colorectal cancer. Lancet. 2010;375:1030–47.
4. O'Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new
American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst.
2004;96:1420–5.
5. Smith TF. Diversity of WD-Repeat Proteins. In: The Coronin Family of Proteins.
Volume 48, edn. Clemen CS, Eichinger L, Rybakin V, editors. Landes Bioscience
& Springer; 2008: Open access: http://www.ncbi.nlm.nih.gov/books/NBK6426/.
Accessed 10th Sept 2015.
6. Clemen CS, Eichinger L, Rybakin V. The Coronin Family of Proteins, vol. 48.
Berlin: Landes Bioscience & Springer; 2008.
7. Eckert C, Hammesfahr B, Kollmar M. A holistic phylogeny of the coronin
gene family reveals an ancient origin of the tandem-coronin, defines a new
subfamily, and predicts protein function. BMC Evol Biol. 2011;11:268.
8. Morgan RO, Fernandez MP. Molecular Phylogeny and Evolution of the
Coronin Gene Family. In: The Coronin Family of Proteins. Volume 48, ed.
Clemen CS, Eichinger L, Rybakin V, editors: Landes Bioscience & Springer;
2008: Open access: http://www.ncbi.nlm.nih.gov/books/NBK6377/. Accessed
10th Sept 2015.
9. Xavier C-P, Eichinger L, Fernandez MP, Morgan RO, Clemen CS. Evolutionary
and Functional Diversity of Coronin Proteins. In: The Coronin Family of
Proteins. Volume 48, ed. Clemen CS, Eichinger L, Rybakin V, editors. Landes
Bioscience & Springer; 2008: Open access: http://www.ncbi.nlm.nih.gov/books/
NBK6170/. Accessed 10th Sept 2015.
10. Rybakin V, Clemen CS. Coronin proteins as multifunctional regulators of the
cytoskeleton and membrane trafficking. Bioessays. 2005;27:625–32.
11. Marshall TW, Aloor HL, Bear JE. Coronin 2A regulates a subset of focal-adhesion-
turnover events through the cofilin pathway. J Cell Sci. 2009;122:3061–9.
12. Yoon HG, Chan DW, Huang ZQ, Li J, Fondell JD, Qin J, et al. Purification and
functional characterization of the human N-CoR complex: the roles of
HDAC3, TBL1 and TBLR1. EMBO J. 2003;22:1336–46.
13. Huang W, Ghisletti S, Saijo K, Gandhi M, Aouadi M, Tesz GJ, et al. Coronin
2A mediates actin-dependent de-repression of inflammatory response
genes. Nature. 2011;470:414–8.
14. Yong HY, Koh MS, Moon A. The p38 MAPK inhibitors for the treatment of
inflammatory diseases and cancer. Expert Opin Investig Drugs. 2009;18:1893–905.
15. Chiacchiera F, Matrone A, Ferrari E, Ingravallo G, Lo Sasso G, Murzilli S, et al.
p38alpha blockade inhibits colorectal cancer growth in vivo by inducing a
Rastetter et al. BMC Cancer  (2015) 15:638 Page 15 of 16
switch from HIF1alpha- to FoxO-dependent transcription. Cell Death Differ.
2009;16:1203–14.
16. Wakeman D, Schneider JE, Liu J, Wandu WS, Erwin CR, Guo J, et al. Deletion
of p38-alpha mitogen-activated protein kinase within the intestinal
epithelium promotes colon tumorigenesis. Surgery. 2012;152:286–93.
17. Comes F, Matrone A, Lastella P, Nico B, Susca FC, Bagnulo R, et al. A novel cell
type-specific role of p38alpha in the control of autophagy and cell death in
colorectal cancer cells. Cell Death Differ. 2007;14:693–702.
18. Karkhanis V, Hu YJ, Baiocchi RA, Imbalzano AN, Sif S. Versatility of PRMT5-induced
methylation in growth control and development. Trends Biochem Sci.
2011;36:633–41.
19. Tanaka H, Hoshikawa Y, Oh-hara T, Koike S, Naito M, Noda T, et al. PRMT5, a
novel TRAIL receptor-binding protein, inhibits TRAIL-induced apoptosis via
nuclear factor-kappaB activation. Mol Cancer Res. 2009;7:557–69.
20. Noegel AA, Blau-Wasser R, Sultana H, Muller R, Israel L, Schleicher M, et al.
The cyclase-associated protein CAP as regulator of cell polarity and cAMP
signaling in Dictyostelium. Mol Biol Cell. 2004;15:934–45.
21. Xiong H, Rivero F, Euteneuer U, Mondal S, Mana-Capelli S, Larochelle D,
et al. Dictyostelium Sun-1 connects the centrosome to chromatin and
ensures genome stability. Traffic. 2008;9:708–24.
22. Kilmartin JV, Wright B, Milstein C. Rat monoclonal antitubulin antibodies
derived by using a new nonsecreting rat cell line. J Cell Biol. 1982;93:576–82.
23. Villanueva MA. Electrotransfer of proteins in an environmentally friendly
methanol-free transfer buffer. Analytical biochemistry. 2008;373:377–9.
24. Langanger G, De Mey J, Adam H. 1,4-Diazobicyclo-(2,2,2)-octane (DABCO)
retards the fading of immunofluorescence preparations. Mikroskopie.
1983;40:237–41.
25. Rick M, Ramos Garrido SI, Herr C, Thal DR, Noegel AA, Clemen CS. Nuclear
localization of Annexin A7 during murine brain development. BMC
Neurosci. 2005;6:25.
26. Suzuki K, Bose P, Leong-Quong RY, Fujita DJ, Riabowol K. REAP: A two
minute cell fractionation method. BMC Res Notes. 2010;3:294.
27. Thal D, Xavier CP, Rosentreter A, Linder S, Friedrichs B, Waha A, et al.
Expression of coronin-3 (coronin-1C) in diffuse gliomas is related to
malignancy. J Pathol. 2008;214:415–24.
28. Ziemann A, Hess S, Bhuwania R, Linder S, Kloppenburg P, Noegel AA, et al.
CRN2 enhances the invasiveness of glioblastoma cells. Neuro Oncol.
2013;15:548–61.
29. Clemen CS, Tangavelou K, Strucksberg KH, Just S, Gaertner L, Regus-Leidig
H, et al. Strumpellin is a novel valosin-containing protein binding partner
linking hereditary spastic paraplegia to protein aggregation diseases. Brain.
2010;133:2920–41.
30. Madlener S, Rosner M, Krieger S, Giessrigl B, Gridling M, Vo TP, et al. Short
42 degrees C heat shock induces phosphorylation and degradation of
Cdc25A which depends on p38MAPK, Chk2 and 14.3.3. Hum Mol Genet.
2009;18:1990–2000.
31. Sheridan DL, Kong Y, Parker SA, Dalby KN, Turk BE. Substrate discrimination
among mitogen-activated protein kinases through distinct docking
sequence motifs. J Biol Chem. 2008;283:19511–20.
32. van Dijk M, Halpin-McCormick A, Sessler T, Samali A, Szegezdi E. Resistance
to TRAIL in non-transformed cells is due to multiple redundant pathways.
Cell Death Dis. 2013;4, e702.
33. Wang ZG, Jia MK, Cao H, Bian P, Fang XD. Knockdown of Coronin-1C
disrupts Rac1 activation and impairs tumorigenic potential in hepatocellular
carcinoma cells. Oncol Rep. 2013;29:1066–72.
34. Ren GP, Tian QMD, An YMD, Feng BP, Lu YP, Liang JP, et al. Coronin 3
promotes gastric cancer metastasis via the up-regulation of MMP-9 and
cathepsin K. Mol Cancer. 2012;11:67.
35. Roadcap DW, Clemen CS, Bear JE. The Role of Mammalian Coronins in
Development and Disease. In: The Coronin Family of Proteins. Volume 48,
ed. Clemen CS, Eichinger L, Rybakin V, editors. Landes Bioscience &
Springer; 2008: Open access: http://www.ncbi.nlm.nih.gov/books/NBK6528/.
Accessed 10th Sept 2015.
36. Wu L, Peng CW, Hou JX, Zhang YH, Chen C, Chen LD, et al. Coronin-1C is a
novel biomarker for hepatocellular carcinoma invasive progression
identified by proteomics analysis and clinical validation. J Exp Clin Cancer
Res. 2010;29:17.
37. Luan SL, Boulanger E, Ye H, Chanudet E, Johnson N, Hamoudi RA, et al.
Primary effusion lymphoma: genomic profiling revealed amplification of
SELPLG and CORO1C encoding for proteins important for cell migration.
J Pathol. 2010;222:166–79.
38. Moreno-Bueno G, Sanchez-Estevez C, Cassia R, Rodriguez-Perales S, Diaz-Uriarte
R, Dominguez O, et al. Differential gene expression profile in endometrioid and
nonendometrioid endometrial carcinoma: STK15 is frequently overexpressed
and amplified in nonendometrioid carcinomas. Cancer Res. 2003;63:5697–702.
39. Moreno-Bueno G, Cubillo E, Sarrio D, Peinado H, Rodriguez-Pinilla SM, Villa
S, et al. Genetic profiling of epithelial cells expressing E-cadherin repressors
reveals a distinct role for Snail, Slug, and E47 factors in epithelial-
mesenchymal transition. Cancer Res. 2006;66:9543–56.
40. Winter SC, Buffa FM, Silva P, Miller C, Valentine HR, Turley H, et al. Relation
of a hypoxia metagene derived from head and neck cancer to prognosis of
multiple cancers. Cancer Res. 2007;67:3441–9.
41. Zhao H, Kim Y, Wang P, Lapointe J, Tibshirani R, Pollack JR, et al. Genome-wide
characterization of gene expression variations and DNA copy number changes
in prostate cancer cell lines. Prostate. 2005;63:187–97.
42. Kim DH, Bae J, Lee JW, Kim SY, Kim YH, Bae JY, et al. Proteomic analysis of
breast cancer tissue reveals upregulation of actin-remodeling proteins and
its relevance to cancer invasiveness. Proteomics Clin Appl. 2009;3:30–40.
43. Klopfleisch R, Klose P, Weise C, Bondzio A, Multhaup G, Einspanier R, et al.
Proteome of metastatic canine mammary carcinomas: similarities to and
differences from human breast cancer. J Proteome Res. 2010;9:6380–91.
44. Wang W, Goswami S, Lapidus K, Wells AL, Wyckoff JB, Sahai E, et al.
Identification and testing of a gene expression signature of invasive carcinoma
cells within primary mammary tumors. Cancer Res. 2004;64:8585–94.
45. Olson MF, Sahai E. The actin cytoskeleton in cancer cell motility. Clin Exp
Metastasis. 2009;26:273–87.
46. Kimura T, Taniguchi S, Niki I. Actin assembly controlled by GDP-Rab27a is
essential for endocytosis of the insulin secretory membrane. Arch Biochem
Biophys. 2010;496:33–7.
47. Xavier CP, Rastetter RH, Blomacher M, Stumpf M, Himmel M, Morgan RO, et
al. Phosphorylation of CRN2 by CK2 regulates F-actin and Arp2/3 interaction
and inhibits cell migration. Sci Rep. 2012;2:241.
48. Castro-Castro A, Ojeda V, Barreira M, Sauzeau V, Navarro-Lerida I, Muriel O,
et al. Coronin 1A promotes a cytoskeletal-based feedback loop that
facilitates Rac1 translocation and activation. EMBO J. 2011;30:3913–27.
49. Swaminathan K, Muller-Taubenberger A, Faix J, Rivero F, Noegel AA. A
Cdc42- and Rac-interactive binding (CRIB) domain mediates functions of
coronin. Proc Natl Acad Sci U S A. 2014;111:E25–33.
50. Williams HC, San Martin A, Adamo CM, Seidel-Rogol B, Pounkova L, Datla
SR, et al. Role of coronin 1B in PDGF-induced migration of vascular smooth
muscle cells. Circ Res. 2012;111:56–65.
51. Mueller P, Massner J, Jayachandran R, Combaluzier B, Albrecht I, Gatfield J,
et al. Regulation of T cell survival through coronin-1-mediated generation of
inositol-1,4,5-trisphosphate and calcium mobilization after T cell receptor
triggering. Nat Immunol. 2008;9:424–31.
52. Jayachandran R, Sundaramurthy V, Combaluzier B, Mueller P, Korf H,
Huygen K, et al. Survival of mycobacteria in macrophages is mediated
by coronin 1-dependent activation of calcineurin. Cell. 2007;130:37–50.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Rastetter et al. BMC Cancer  (2015) 15:638 Page 16 of 16
